Search

GlaxoSmithKline PLC

Fermé

SecteurSoins de santé

1,389.5 -0.22

Résumé

Variation du prix de l'action

24h

Actuel

Min

1378.5

Max

1397

Chiffres clés

By Trading Economics

Revenu

559M

501M

Ventes

105M

8.1B

P/E

Moyenne du Secteur

21.557

57.333

BPA

23.2

Rendement du dividende

4.79

Marge bénéficiaire

6.172

Employés

68,629

EBITDA

-52M

1.1B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+13.6% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

4.79%

2.63%

Prochains Résultats

30 avr. 2025

Date du Prochain Dividende

10 juil. 2025

Date du Prochain Détachement de Dividende

15 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-5.9B

54B

Ouverture précédente

1389.72

Clôture précédente

1389.5

GlaxoSmithKline PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

9 avr. 2025, 09:39 UTC

Principaux Mouvements du Marché

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

5 févr. 2025, 11:32 UTC

Résultats

GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook -- 2nd Update

5 févr. 2025, 08:56 UTC

Résultats

Correction to GSK Article

5 févr. 2025, 08:24 UTC

Résultats

GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After Beating Market Views -- Update

5 févr. 2025, 07:43 UTC

Résultats

GSK Expects Further Profit Growth After Beating Market Views

23 avr. 2025, 21:48 UTC

Actualités

Shingles Vaccine Appears to Lower Dementia Risk -- WSJ

23 avr. 2025, 20:47 UTC

Actualités

Shingles Vaccine Appears to Lower Dementia Risk -- WSJ

23 avr. 2025, 20:40 UTC

Actualités

Shingles Vaccine Appears to Lower Dementia Risk -- WSJ

15 avr. 2025, 09:55 UTC

Market Talk

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

9 avr. 2025, 07:23 UTC

Market Talk

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

3 avr. 2025, 08:41 UTC

Market Talk

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3 avr. 2025, 08:36 UTC

Market Talk

U.K. Pharma to Have Some Share-Price Volatility But Long-Term Outlook Remains Intact -- Market Talk

3 avr. 2025, 07:51 UTC

Market Talk

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

2 avr. 2025, 09:27 UTC

Actions en Tendance

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

26 mars 2025, 22:29 UTC

Actualités

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- 2nd Update

26 mars 2025, 19:19 UTC

Actualités

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- Update

26 mars 2025, 17:39 UTC

Actualités

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- WSJ

19 mars 2025, 14:50 UTC

Actualités

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

17 mars 2025, 09:00 UTC

Actualités

Pfizer Has a New Playbook for Reviving Sales -- And It's Starting to Pay Off -- WSJ

24 févr. 2025, 07:05 UTC

Acquisitions, Fusions, Rachats

GSK Completes Acquisition of IDRx

14 févr. 2025, 11:38 UTC

Actualités
Résultats

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

14 févr. 2025, 11:30 UTC

Actualités
Résultats

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

5 févr. 2025, 15:33 UTC

Market Talk
Résultats

GSK's Pipeline Has to Prove It Can Counter Concerns Over Vaccine Business -- Market Talk

5 févr. 2025, 08:38 UTC

Market Talk
Résultats

GSK Needs to Show It Can Navigate Vaccines Challenge -- Market Talk

5 févr. 2025, 07:05 UTC

Résultats

GSK PLC Had Seen 2031 Sales Outlook at More Than GBP38B

5 févr. 2025, 07:04 UTC

Résultats

GSK PLC Sees 2031 Sales Outlook at More Than GBP40B

5 févr. 2025, 07:03 UTC

Résultats

GSK PLC Sees 2025 Adjusted EPS Growth of 6%-8%

5 févr. 2025, 07:03 UTC

Résultats

GSK PLC Raises Mid-Term View

5 févr. 2025, 07:03 UTC

Résultats

GSK PLC Sees 2025 Adjusted Operating Growth of 6% - 8%

5 févr. 2025, 07:02 UTC

Résultats

GSK PLC Sees 2025 Turnover Growth of 3% to 5%

GlaxoSmithKline PLC prévision

Objectif de Prix

By TipRanks

13.6% hausse

Prévisions sur 12 Mois

Moyen 1,583.64 GBX  13.6%

Haut 2,290 GBX

Bas 1,350 GBX

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

11 ratings

1

Achat

8

Maintien

2

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.